Showing results (1-10 of 5) with videos related to
Sort By:
Pageof 1
Ecancermedicalscience|October 6, 2022
CDK 4/6 inhibitors for adjuvant therapy in early breast cancer-Do we have a clear winner?Amol Akhade, Simon Van Wambeke, Bishal GyawaliEcancermedicalscience|February 23, 2023
Highlights from Choosing Wisely 2022 for Resource Limited Settings: Reducing Low Value Cancer Care for Sustainability conference, 17th-18th September, Mumbai, IndiaAmol Akhade, Bishal Gyawali, Richard Sullivan, et al.JCO Global Oncology|June 24, 2026
Leveraging Social Media for Oncology Education and Practice: Perspective From Low- and Middle-Income CountriesKaran Sood, Amol Akhade, Nihanthy D Sreenath, et al.European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategiesPablo Jiménez-Labaig, Failah Mohamed, Nur Jihan Irwan Tan, et al.South Asian Journal of Cancer|March 24, 2025
Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2-ve Early Breast Cancer (EBC)Purvish M Parikh, Amish Vora, Rajan Yadav, et al.Pageof 1